Novo Nordisk A/S. Every tracked FinTwit mention of $NVO, newest first. 291 mentions since the first on Jul 29, 2025. See the price chart.
July 2026 · 2 mentions
Jul 15
The Future Investors — $NVO Novo Nordisk received EU approval for Wegovy pill, making it the first oral GLP-1 weight-loss treatment available across the European Union 💊🇪🇺
The EC also approved the n…↗
Jul 10
PhotonBull — @TacticzH Awesome list!
Loce $MELI. Still not sure about $NVO to be honest. I think they are a buy here, but also think $LLY might just be the 'obvious' better buy. But again, the…↗
TheValueist — $LLY $NVO Worth a ~$500/month experiment?
EXECUTIVE OVERVIEW
As of June 2026, the best-supported conclusion is that GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists h…↗
Jun 19
TheValueist — $LLY $NVO I have heard from multiple people that taking GLP-1/GIPs have made them a better investor. There is the beginnings of meaningful research on how GLP-1/GIPs reduce impulsi…↗
InvestmentGuru — Everyone’s asking what to buy in 2026.
The answer’s been in the executive orders the whole time.
The reshoring of America is real. And it starts with the ground-level stuff nobo…↗
May 24
InvestmentGuru — THE THEMATIC WATCHLIST — 2025 EDITION
Every mega-trend. Every sector. One list.This is how I’m thinking about capital allocation across the next cycle 👇
AI
→ $GOOGL $PLTR $NVDA $…↗
May 14
Shay Boloor — $HIMS is now accepting orders for the $NVO Ozempic Pill on its website at $149/month.
Hims is expanding its branded GLP-1 offering beyond injections giving the platform another wa…↗
The Future Investors — $NVO $LLY Novo Nordisk is extending its early lead in the oral obesity race, with Wegovy ramping much faster than Eli Lilly’s Foundayo 💊
Week 2 Prescriptions 📊
Wegovy: 18.4K
F…↗
Apr 24
Shay Boloor — JPMorgan initiates $HIMS at Overweight with a $35 price target.
The core bet is that the $NVO deal turns Hims into a scaled DTC healthcare platform that gives Hims a path to scale…↗
Apr 23
SandemanStocks — $HIMS offering Lilly products on its platform has possibly set a precedent for the rest of Pharma. First $NVO…but by itself it could look like a 1 off exclusive partnership.
Bu…↗
The Future Investors — $NVO Novo Nordisk launched Wegovy subscription plans (3-12 months) in the US , offering lower, predictable monthly pricing with savings up to $1,200/year 💉💸 https://t.co/Mlz5pU6s…↗
Mar 19
The Future Investors — $NVO FDA approved a higher-dose version of Novo Nordisk’s Wegovy 💉
In trials, the new dose helped patients lose 20.7% of body weight over 72 weeks and is expected to launch in Ap…↗
Mar 16
Black Panther Capital — $NBIS is dragging the whole sector up right now.
2 deals within short time with $NVDA and $META.
I’m invested in both $NBIS and $IREN.
I believe fully in both cases and manageme…↗
Black Panther Capital — My dad invest based on good news…
Should we tell him?
$PYPL $NVO $DUOL $HIMS $PATH $EOSE https://t.co/2sKzqhVqoj↗
Feb 25
Tradable Astronaut — 🔥New feature added🔥
Should we start posting these daily?👀
$ACLX l $UCTT l $LITE l $GRAL l $U l $LMND l $NVO https://t.co/GjWbj6MNEH
January 2026 · 69 mentions
Jan 31
The Future Investors — What a week it was 😮
Next week looks just as intense 🔥
A full week of earnings:
$PLTR $AMD $LLY $NVO $UBER $ARM $QCOM $GOOGL $AMZN $IREN and many more 📊
Which one are you watc…↗
Jan 31
Trade Whisperer — 🟦 $NVO First (M) BLUE candle in years, aligning with a key volume concentration level.
Something is brewing. https://t.co/sTJ7fdTZVh↗
Jan 27
Jason Luongo — January 27th 2026
Buy leaps
Sell puts
Hold shares
Go to the gym
$IREN $AMZN $NBIS $ONDS $LTRX $OSS
$AMKR $HIMS $NVO https://t.co/5C2w8Os8lp↗
Jan 26
Jason Luongo — @TheRonnieVShow I’m trying to decide if I’m bullish or not. Peptides are going to transform healthcare in my opinion and $HIMS is the only telehealth company that’s owns a USA pept…
December 2025 · 32 mentions
Dec 31
Black Panther Capital — GM fam & friends, I’m turning 35 today! 🎁
Another year of building high conviction while balancing family life. Markets reward patience and discipline.
Things I’ll cover in this…↗
Dec 30
Mike Investing — $NVO will see a V shape recovery back above the 200SMA at $83 very soon.
With a 3.7% dividend, 24% YoY revenue growth and a 25% YoY EPS $NVO is a safe haven.
At just a 12x P/E pr…↗
Dec 30
InvestmentGuru — $LLY
$NVO
Novo and Lilly cut prices of weight-loss drugs in China↗
Dec 30
InvestmentGuru — $NKE
$ALAB
$TTD
$NVO
$NFLX
In a market driven by rotation and selective strength, these names stand out as value buying opportunities.
November 2025 · 23 mentions
Nov 30
Mike Investing — These 7 stocks remain strong buys and will outperform the markets as we head into 2026…
1. $TSLA at $430
2. $SOFI at $29
3. $NVO at $49
4. $LULU at $180
5. $ORCL at $190
6. $OSCR…↗
Nov 27
Mike Investing — This year I’ve called the bottoms and caught…
1. $TSLA at $210
2. $LMND at $35
3. $NBIS at $62
4. $AMD at $75
5. $PLTR at $65
6. $HOOD at $30
While I do still really like these 6…↗
Nov 26
Mike Investing — These 7 stocks remain the Best Buy’s as we head into 2026, and are going to outperform the markets by a significant margin…
1. $META
2. $UNH
3. $NVO
4. $OSCR
5. $IREN
6. $SOFI
7.…↗
The Future Investors — $NVO $PFE $MTSR Novo Nordisk outbid Pfizer for U.S. biotech Metsera with a $9B offer, which Metsera called 'superior.' Pfizer slammed the move as "reckless." The deal strengthens N…↗
Oct 30
Adam Feuerstein ✡️ — M&A drama, with a dose of "America First" politics! So much fun...
Novo Nordisk $NVO makes offer for obesity-focused Metsera $MTSR, aiming to outbid Pfizer $PFE https://t.co/…↗
Oct 30
Adam Feuerstein ✡️ — $PFE calls $NVO bid for $MTSR "reckless and unprecedented..."
Also, Bourla playing his Trump card, literally...
"It is an attempt by a company with a dominant market position to…↗
Adam Feuerstein ✡️ — Scholar Rock $SRRK SMA drug rejected due to problems at $NVO -owned contract manufacturing site https://t.co/DFR1iOuvlc↗
Sep 12
Mike Investing — If you missed out on the $UNH rally then your next 3 opportunities are here and ready to breakout.
These next 3 setups are expected to run 200/300% over the next few months…
1. $…↗
Sep 10
Adam Feuerstein ✡️ — Novo Nordisk $NVO to cut 11% of workforce as it seeks to regain competitive edge https://t.co/xeqdsQy3wr via @DrewQJoseph↗
Sep 7
Mike Investing — As rotation in the market occurs in guidance to seasonality, healthcare stocks will now begin to powerfully outperform.
These 5 stocks will see extensive rally’s heading into Nove…
August 2025 · 8 mentions
Aug 21
Adam Feuerstein ✡️ — What a unique situation.... $NVO buys a manufacturing plant for Wegovy, but it's basically the worst facility in the U.S. and as a result, a bunch of other drug makers who use it…↗
Aug 21
Adam Feuerstein ✡️ — U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, FDA finds
Plant, once owned by $CTLT and now owned by Novo Nordisk $NVO, is widely u…↗
Aug 19
Adam Feuerstein ✡️ — "Pharm to table"
It's the clever buzzphrase bandied around by pharma insiders when promoting their plans to sell drugs directly to consumers.
Cut out the insurers and the PBMs…↗
Mike Investing — $HIMS is going to breakout above $100+ very soon…
Since the $HIMS & $NVO -35% deal termination dip $HIMS is now up over 57%+ and isn’t stopping anytime soon.
With 111% YoY re…↗
Jul 29
SpotGamma — $NVO is down 20% and IV's for downside strikes are down https://t.co/EIwcutVHRg↗
Jul 29
Adam Feuerstein ✡️ — Novo Nordisk $NVO names new CEO as it cuts growth outlook https://t.co/NdPiHrKwvR via @elaineywchen↗
Jul 29
SpotGamma — $NVO is getting "mercked" today - down 25% to ~50.
Interesting its <55 where options positions essentially cease to exist.
Given that, and my boredom with the 29bps expected…
The Future Investors — $NVO Novo Nordisk has launched its Wegovy weight-loss pill in the UAE making it the first country outside the U.S. where the treatment is available 💊🇦🇪
More international launc…↗
— $HIMS wants to become the consumer-facing front door for healthcare but the market still needs proof the $NVO partnership can turn GLP-1 demand into profitable growth.
After the c…
Shay Boloor — $NVO says higher-dose Wegovy showed 27.7% average weight loss at 72 weeks in early responders.
A separate analysis found 84% of the weight loss came from fat mass with visceral fa…↗
May 9
PhotonBull — Seeing a LOT of bullish posts on $HIMS since yesterday, probably due to the ''Trump Is Planning to Fire FDA Commissioner Marty Makary'' headline?
Or is it @kevinxu announcing his…↗
May 9
Serenity — I feel like all the $FISV, $PYPL, $NVO value/dividend investors went extinct this cycle?
Was very popular, even last year…
But if you pivoted to semis like $INTC or $SNDK, you wo…↗
May 7
Shay Boloor — $AMZN Pharmacy is expanding access to $NVO oral Ozempic with same-day prescription delivery across nearly 3,000 U.S. cities.
Amazon also plans to add One Medical pickup kiosks and…↗
May 6
InvestmentGuru — $NVAX $NVO $OSCR all up 10%+
$NVAX Q1 EPS of $2.93 vs. -$0.43 estimate. Massive beat. Matrix-M adjuvant licensing model validating fast.
$NVO Q1 sales +32% to $15.2B. Wegovy hold…↗
The Future Investors — 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸 𝗤𝟭 𝟮𝟬𝟮𝟲 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀 $NVO
EPS: $1.04 vs $1.10 est. ❌
Revenue: $10.87B vs $11.29B est. ❌
𝗢𝘂𝘁𝗹𝗼𝗼𝗸 𝟮𝟬𝟮𝟲
Revenue: -4% to -12% vs -7.4% es…↗
May 2
The Future Investors — Next week is absolutely packed with major earnings reports on deck 🚀
Monday: $PLTR, $DUOL
Tuesday: $SHOP, $AMD, $ANET, $TMDX
Wednesday: $NVO, $ADYEN, $UBER, $AXON
Thursday: $CRWV…↗
— $AGIO -16% on $NVO study outcome in sickle cell disease.
Serenity — It’s still pretty incredible $HIMS is down 44% even after:
1. $NVO de-risking + partnership
2. Multiple global acquisitions expanding DTC distribution network
3. Peptide arc, with…↗
Apr 17
SandemanStocks — Ok, so I was going to sell 300 puts in $HIMS but I feel like there is more upside in buying shares. Just got a starter position with 15,000 shares pre market. I may add on dips.…↗
Apr 15
Serenity — This announcement is the most bullish catalyst for $HIMS revenue re-acceleration to date.
This is amid:
- 30%+ of the float sold short
- new $NVO partnership/lawsuit dropped
- new…↗
Apr 14
The Future Investors — $NVO Novo Nordisk partners with OpenAI to use AI across drug discovery and operations 🤖
AI will help find new treatments faster, improve efficiency, and speed up the path from re…↗
Black Panther Capital — This might be the biggest "tell" of 2026 so far. So please, sit with this for a second:
I was at Easter lunch yesterday with my father-in-law.
This guy has been a investor for 30…↗
Apr 7
KaizenInvestor — Looks like the $HIMS relationship with $NVO is fully restored.
The partnership first collapsed in June 25’, when $HIMS was at $61. https://t.co/nvIDjKKoHB↗
Apr 7
The Future Investors — $NVO Novo Nordisk’s Wegovy HD (7.2 mg) now available nationwide in the U.S. 💉🇺🇸↗
Apr 4
Trade Whisperer — $NVO PINK monthly candle printed at $140. Now at $36.98. Bottom unknown until BLUE shows up.
Get 280+ charts daily. Try it free: https://t.co/UOnxsgc8Ii https://t.co/K3XJcKHRCg↗
Apr 1
KaizenInvestor — 3 stock I think will bounce back in 2026.
1. $HIMS
HIMS is perfectly positioned to capture the new pharma wave. GLP-1 is still the fastest growing TAM outside AI. While the AI T…↗
Adam Feuerstein ✡️ — Eli Lilly’s $LLY obesity pill approved by FDA, setting up fierce competition with Novo Nordisk $NVO https://t.co/9mQ93N6Xe8 via @elaineywchen↗
— $HIMS surprised the market when $NVO dropped its lawsuit against the company and instead moved forward with a partnership.
No one saw this coming.
To be clear - NVO didn’t just d…
InvestmentGuru — $HIMS sentiment shift
The deal between $HIMS and $NVO is a major sentiment changer for investors. Validation from the maker of Ozempic and Wegovy puts $HIMS directly in the grow…↗
Mar 12
Serenity — @alc2022 Makes sense though given $NVO dropping the lawsuit and partnering with $HIMS was a surprise to majority of people.
Definitely caught a lot of people off guard, especially…↗
Mar 11
Serenity — I try to talk about $HIMS from a fundamental standpoint.
But this cannot be understated:
$HIMS directional shorts look trapped.
The stock price is now up 64.15% to $26.5 (still…↗
Mar 11
Lando — @hypergrowth102 You gotta admit that was kind of a curve ball no one expected. $NVO to drop everything and partner? Mike is also a D1 rage baiter I wouldn't take anything to heart…↗
Mar 11
Serenity — $HIMS is now back up 14.22%.
The untapped latent revenue from their their global DTC retail distribution moat is extreme.
And draws parallels to the early acquisitions from $META…↗
Mar 10
Serenity — Does nobody else see the parallels to $HIMS and $META and $HOOD?
$HIMS literally just bought out the largest players around the world:
- Zava (Europe/UK)
- Livewell (Canada)
- E…↗
Mar 9
Serenity — @OM_Strategy Yes the 40% SI made sense earlier.
I was bearish on $HIMS too until $NVO partnered up + dropped the lawsuit, giving $HIMS revenue stream expansion and more regulator…↗
Mar 9
Serenity — @Shiboo9019 Hindsight 20/20.
When I was long $HOOD back at $16, I realized they could expand via Crypto and other methods too.
However, analysts were all giving Robinhood $8-12…↗
Mar 9
Serenity — Feels like people aren't articulating the bull case for $HIMS correctly:
Here's my view.
The main moat of $HIMS is network capture of retail audiences.
And the bull case is lat…↗
Mar 9
Shay Boloor — $NVO CEO said the partnership with $HIMS is meant to make its products accessible to as many patients as possible.
He also pointed to Hims & Hers’ 2.5M-user platform as a dire…↗
Mar 9
Black Panther Capital — I took a position in $HIMS today. Here’s why.
The bear case just died. Let me explain.
For 12 months, the market treated $HIMS like a company living on borrowed time:
> FDA clos…↗
Mar 9
Lando — @NighthawkTradez No way does this happen, $LLY hates $NVO↗
InvestmentGuru — $NVO $HIMS
NOVO CONFIRMS WILL SELL WEGOVY, OZEMPIC ON HIMS & HERS PLATFORM, SHOTS, WEGOVY PILL AVAILABLE ON $HIMS LATER THIS MONTH↗
Mar 9
Serenity — Just in: CEO of $HIMS announces partnership with $NVO.
This is confirmation of the report on Friday from Bloomberg.
With 40%+ of the float sold short and transparency around the…↗
Mar 9
Shay Boloor — $NVO confirms Wegovy and Ozempic will be sold on the $HIMS platform with Wegovy shots and the pill launching later this month.
Hims & Hers will also stop advertising compounde…↗
Mar 9
mon — $NVO officially drops the lawsuit against $HIMS.
> no one expected this outcome so soon.
> lawsuits usually drag on for years.
> so this is a very positive news.
A lot o…↗
Mar 9
Shay Boloor — $HIMS jumps ~48% after $NVO plans to sell its obesity drugs through the Hims platform. https://t.co/UYmhwKF2my↗
Mar 9
KaizenInvestor — It still strikes me how wrongly investors see the GLP-1 drugs. It is not an obesity drug, it is way more than that.
Last year I shared some research on $HIMS and why I think they…↗
Mar 9
Serenity — $HIMS overnight trading will begin soon after finishing Friday at $22.
Previously it traded at $70, but given:
- $NVO / US Gov lawsuit threatening to bankrupt the company
- $HIM…↗
Mar 9
mon — $NVO X $HIMS
They need each other to break out of this downward trend. https://t.co/FxqwIhRJ1y↗
Mar 8
Shay Boloor — $HIMS CEO Andrew Dudum says the GLP-1 obesity drug market could become one of the largest categories in healthcare after $NVO ended its dispute with Hims & agreed to partner.…↗
Mar 7
SandemanStocks — $HIMS serious question. Did the news with $NVO come out only on Bloomberg? Did the companies confirm it? I ask because Bloomberg has been posting false stories all year. Don’t…↗
Mar 7
Serenity — Most people on X make the mistake of getting married to a stock.
If your thesis materially changes with $HIMS or $IREN, so should your position.
If the bull case with $IREN las…↗
Mar 7
Mike Investing — On Monday, $HIMS has the potential to make history…
$NVO has reportedly dropped the lawsuit, & partnered with $HIMS to sell NOVO branded GLP-1’s.
Institutions shorted 40% of $HIM…↗
Mar 7
Leandro — What's Novo's $NVO thinking with this new agreement with $HIMS?
You get more distribution but you also give the impression that you are at the mercy of distributors who can basica…↗
Serenity — Monday could make history.
As one of the largest short squeezes in history could unfold.
> Institutions shorted 40% of $HIMS (extraordinarily large)
> expecting 0 revenue growt…↗
Mar 7
Daniel Koss — Give this man some credit, he called it!! $HIMS $NVO↗
Mar 7
Trade Whisperer — $NVO 76% gone. 19 months. $148 to $36.
One PINK candle flagged this before the first drop. Now $HIMS just showed up at the wreckage. BLUE candle next? 👀
Get 270+ charts daily. T…↗
Mar 7
Antonio Costa — $HIMS +40% in aferthours trading $NVO +2% https://t.co/RLi8dOk5hh↗
Mar 7
Chris Ray — $HIMS investors having a wild Friday night tonight after the stock rips +40% after a deal was reached with $NVO to sell obesity drugs together. https://t.co/KhJUMC0TEV↗
Mar 7
Trade Whisperer — $HIMS short interest is ~42% and the stock just ripped +40% after hours on the $NVO partnership news.
When nearly half the float is short and the thesis blows up overnight, the ex…↗
Mar 7
The Future Investors — $HIMS $NVO Novo Nordisk and Hims & Hers Health are reportedly ending their legal feud and planning a partnership to sell obesity drugs like Wegovy on the Hims platform 💉💊
Hi…↗
Mar 7
InvestmentGuru — $HIMS after deals with $NVO https://t.co/xgoDMIGkVm↗
Mar 7
KaizenInvestor — Huge news on $HIMS!
Looks like $NVO dropped the lawsuit and HIMS will sell Novo GLP-1 products again.
Huge win for both parties.
Very happy I added some shares in the last co…↗
Mar 7
Serenity — @pepemoonboy Pretty sure the $HIMS news caught everyone off guard, especially all the short sellers.
Did not expect a $HIMS partnership with $NVO out of all things.↗
Mar 7
Serenity — Congrats to the $HIMS holders, stock back up 37% after hours.
It looks like $NVO dropped the lawsuit and partnered with $HIMS to sell NOVO branded GLP-1s.
Given HIMS was once tra…↗
Mar 7
Trade Whisperer — $HIMS +30% AH on $NVO partnership.
"Novo and Hims End Feud, Will Sell Obesity Drugs Together" -Bloomberg https://t.co/52oRGzbbmE↗
Mar 7
Jason Luongo — $NVO & $HIMS TO ANNOUNCE PARTNERSHIP ON MONDAY
This is AMAZING news for $HIMS shareholders https://t.co/wfiPGGdDkM↗
Mar 6
Jason Luongo — Which ticker is the most likely to 3x in 3 years?
- $EOSE at $7
- $IBRX at $10
- $ONDS at $10
- $PGY at $11
- $OSCR at $14
- $HIMS at $15
- $CIFR at $17
- $ZETA at $17
- $SOFI at…↗
Mar 5
Serenity — @R1chardMaur1ce $HIMS got sued to oblivion by $NVO and the US GOV.
Compound weight loss drugs was their primary avenue for revenue growth and potential lawsuit means red flags fo…↗
Mar 1
Kevin Maro — @longinvest32 You feel strongly about $HIMS? I might buy 1k shares, but I feel like $NVO might be better just because americans are all fat pigs and Ozempic isn't going anywhere↗
Lando — It’s almost like we knew $LLY was better than $NVO
I don’t have any shares, but there’s a reason one is thrown into the “Mag 8” and one is far from it↗
Feb 23
Shay Boloor — @PolymarketMoney Hard not to wonder if $NVO should just bite the bullet and make a move on $VKTX at $100+.↗
Feb 23
Shay Boloor — $NVO down ~15% after its next-gen obesity drug CagriSema missed the primary endpoint in Phase 3 vs. $LLY Zepbound. https://t.co/EfyXw4UT3R↗
Feb 23
Adam Feuerstein ✡️ — Novo Nordisk’s $NVO next-gen obesity drug stumbles in $LLY comparison study https://t.co/J4u8f9BHdB via @DrewQJoseph↗
Feb 23
The Future Investors — $NVO Novo Nordisk reported that CagriSema delivered 23% weight loss over 84 weeks but failed to match tirzepatide in a head-to-head trial.
The drug was well tolerated, with higher…↗
Feb 20
Jason Luongo — Which ticker is the most likely to 2x in 2 years?
- $TE ~ $6
- $OSS ~ $8
- $VG ~ $10
- $EOSE ~ $11
- $ONDS ~ $11
- $OSCR ~ $14
- $CIFR ~ $15
- $HIMS ~ $16
- $ZETA ~ $16
- $SOFI ~…↗
Feb 17
Jason Luongo — Every stock on this list is cheaper than it should be.
$IREN is undervalued
$AMZN is extremely undervalued
$META is undervalued
$NBIS is undervalued
$PATH is extremely undervalued…↗
Feb 17
Jason Luongo — These opportunities will create millionaires in the next 3 years.
- $META at $639
- $AMZN at $198
- $NBIS at $97
- $LMND at $63
- $IREN at $42
- $CIFR at $16
- $OSCR at $13
- $PAT…↗
Feb 17
Midas — Which Mike Alfred stock do you think will go parabolic this year?
$ASST
$IREN
$CIFR
$OPEN
$BKKT
$SBET
$SUIG
$CLSK
$NVO
$STZ
$DEO
I'm betting on $IREN.↗
Feb 9
Black Panther Capital — @pepemoonboy 😂😂 that will with 1.000% certainty be $NVO. Come on man. That’s the logic.↗
Feb 9
Adam Feuerstein ✡️ — $NVO general counsel says in our interview:
$HIMS relies on "sham mass personalization of semaglutide."
HIMS' attempt to sell a compounded version of the Wegovy pill is "like th…↗
Feb 9
Adam Feuerstein ✡️ — Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel tells STAT in exclusive interview. $NVO $HIMS
https://t.co/YYgSUug19o via @elaineywch…↗
Shay Boloor — $HIMS extends losses to ~22% after $NVO said it is suing over knockoff obesity drugs.
This comes as the FDA signals full enforcement on compounded GLP 1s and the company exits com…↗
Feb 9
mon — $NVO sues $HIMS over cheaper copycat versions of Wegovy pill, injections - CNBC.
Stock down 20% pre-market.
$18.42 -> The same price as it was back in 2024. https://t.co/MuGya…↗
Feb 9
Adam Feuerstein ✡️ — BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent https://t.co/44Ndx293d4 via @pharmalot↗
Adam Feuerstein ✡️ — HHS asks Justice Department to probe Hims & Hers $HIMS over its cheaper compounded version of $NVO Wegovy https://t.co/OGyGcy3lWM via @pharmalot↗
Feb 6
The Future Investors — $HIMS $NVO The FDA plans to restrict GLP-1 ingredients in non-approved compounded drugs, citing safety and legal concerns. The FDA also warned against misleading marketing, and Him…↗
Feb 6
Serenity — @green_pumpsie Solana and crypto assets were “illegal” 2 years ago and many founders were threatened with enforcement + jail for dealing with “securities”.
The timing of this afte…↗
Feb 6
Serenity — Why does this looks eerily similar to Gary Gensler trying to jail $HOOD and Coinbase founders back in 2022?
$HIMS is doing something innovative now 4 years later and big pharma is…↗
unusual_whales — The community page displays options contracts that have been posted in the subscriber only channels of the UW Discord: https://t.co/1JNDGTqZYY
Community page:
https://t.co/hnfCUw…↗
Feb 6
Jason Luongo — @Craigster771 @DrMakaryFDA You think having a monopoly on drugs that can help people’s lives and price gouging people and forcing them to go through the broken health care system t…↗
Feb 6
The Future Investors — $NVO $LLY Trump launches online prescription drug platform TrumpRx claiming the lowest prescription drug prices globally.
Targets a wide range of medications, o.a. blockbuster GLP…↗
Feb 5
KaizenInvestor — If you bought $HIMS 5 years ago, your investment would be down 2%.
In the meantime
- Revenue growth: +1,044%
- Subscriber growth: +346%
- Gross profit margin: 29% -> 75%
- FCF ma…↗
Feb 5
Adam Feuerstein ✡️ — Novo Nordisk $NVO accuses Hims & Hers $HIMS of ‘illegal mass compounding’ over a cheaper version of Wegovy pill https://t.co/l6xgvgPWNK via @pharmalot @damiangarde↗
Lando — Well this just got interesting $NVO & $HIMS↗
Feb 5
Shay Boloor — $NVO CEO criticized $HIMS compounded GLP-1 pill saying patients would be “wasting $49” because the drug won’t be properly absorbed.
The comments were made on a call with analysts.…↗
Feb 5
The Future Investors — $HIMS $NVO Hims & Hers is launching a compounded pill version of Novo Nordisk’s Wegovy starting at $49 per month. The move undercuts the brand’s price and increases pricing pre…↗
Feb 5
Shay Boloor — $HIMS is launching a compounded semaglutide pill at $49 intro pricing and ~$99/month on subscription vs. ~$199/month for $NVO Wegovy pill.
Same active ingredient as Wegovy but at…↗
Feb 5
Jason Luongo — $HIMS launches a copy of $NVO Wegovy pill for $49 a month. The stock is up over 10% premarket on the news.
This is HUGE news https://t.co/0yaatYJE0N↗
TheValueist — I've committed to focusing my X account on TMT/Power, but it's hard not to look at this. I've been a long-term $LLY investor for many years. The divergence from $NVO is wild and im…↗
Feb 4
Jason Luongo — @topsecretstocks But seriously. $NVO is shooting themselves in the foot.↗
Adam Feuerstein ✡️ — Novo Nordisk $NVO lowers sales, profits forecast as Wegovy faces growing competition https://t.co/MUm3l4KM8c via @elaineywchen↗
Feb 3
mon — This year has been a disaster for a number of companies.
Just today:
$PYPL -19%
$FUBO -21%
$NVO -14%
Another retail favorite backed by popular FinX influencers just hit a new low…↗
Feb 3
The Future Investors — 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸 𝗤𝟰 𝟮𝟬𝟮𝟱 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀 $NVO
EPS: $1.02 vs $0.94 est. ✅
Revenue: $12.53B vs $12.17B est. ✅
𝗢𝘂𝘁𝗹𝗼𝗼𝗸 𝟮𝟬𝟮𝟲
Revenue: -5% to -13% vs -2.3% est…↗
Feb 3
Shay Boloor — $NVO warned on pricing pressure and guided 2026 adjusted sales growth of -5% to -13% (vs. +2% estimates).
Management expects a U.S. decline driven by lower realized prices under “…↗
Chris — Right before the news 🚨
8,482 $NVO $54 puts
💰 Entry: ~$560K
⏱️ Moments later:
💰 ~$3.2M value
📈 +485%
Flagged in real-time by Trade Echo.↗
Feb 3
Adam Feuerstein ✡️ — $NVO down sharply on early release of earnings, including weaker-than-expected sales guidance for 2026.↗
Feb 3
unusual_whales — $NVO has been halted
Get halt notifications sent to your device: https://t.co/kGeAGtelLT https://t.co/s5cudDoGCd↗
Feb 2
Jason Luongo — ALL OF THESE STOCKS REPORT EARNINGS THIS WEEK!
Monday, February 2:
The Walt Disney Company $DIS
Palantir Technologies $PLTR
NXP Semiconductors $NXPI
Simon Property Group $SPG
Tys…↗
Jason Luongo — @investingluc Great write up Luc. I take peptides myself and have seen the improvements it’s made in my life. It’s something I’ve thinking about a lot and have been trying to figur…↗
Jan 25
Midas — Which Mike Alfred stock do you think will go parabolic this year?
$ASST
$IREN
$CIFR
$OPEN
$BKKT
$SBET
$SUIG
$CLSK
$NVO
$STZ
$DEO
I'm betting on $IREN + $ASST.↗
Jan 24
Mike Investing — We are vastly outperforming the markets yet again in just 24 days.
So far this year these picks were called out:
$ASTS +55%
$EOSE +45%
$IREN +42%
$PL +40%
$LMND +34%
$RKLB +30%…↗
Jan 23
Mike Investing — These things are next to happen:
$ASTS is going to $150, then slightly pulling back, & running to $220+.
$RKLB is squeezing to $140+ ahead of the SpaceX IPO.
$ZETA will pop 10/2…↗
Jan 23
Jason Luongo — You check your phone 30 times a day hoping your trade finally turns green.
It doesn't. You sell at a loss. You find another setup.
Repeat.
Six months later you've paid more in f…↗
Jan 23
Mike Investing — $NVO has officially blown through its 200SMA confirming an incoming major squeeze…
With a 25% YoY EPS, 24% Revenue growth YoY, & only a 14x P/E, $NVO remains an obvious hold.…↗
The Future Investors — Glassdoor has shared its Best Places to Work for 2026 👥🏆
Below the most notable companies and their rankings 👇
3. $NVDA | Nvidia
7. $NOW | ServiceNow
11. $GOOGL | Alphabet
20.…↗
Jan 18
Serenity — @StockSavvyShay I'm a bull that's excited about Greenland trade tensions.
US defense like $UAVS and $DPRO are likely to benefit. Same with rare earth/critical materials.
Ca…↗
Jan 18
Tradable Astronaut — $NVO Shares are up 33% & Leaps up 100% !
Good start to the year! https://t.co/WmDcvUUL1m↗
Jan 18
Mike Investing — I’m officially calling it…
$NVO will be the next healthcare stock to see an aggressive rebound rally towards ATH’s.
With 20% YoY revenue growth, 42%+ operating margins, $NVO has…↗
Jan 17
Mike Investing — Over the last few months my callouts have created many millionaires.
Many doubted me on…
$TSLA at $210 & ran to $499+
$IREN at $33 & ran to $59+
$ASTS at $35 & ran to $120+
$RKLB…↗
Jan 16
Mike Investing — You can create generational wealth simply by scrolling on X…
Over the past few weeks I’ve called out:
$ASTS at $35 & ran to $120+
$RKLB at $37 & ran to $98+
$IREN at $3…↗
Jan 16
Shay Boloor — @PolymarketMoney Kind of wild that $NVO is trading at 16x earnings↗
Jan 16
Shay Boloor — $NVO is trading higher after the UK’s MHRA cleared a higher-dose Wegovy option at 7.2 mg once weekly for adults with obesity.
The approval pushes dosing well above the current 2.4…↗
Jan 16
InvestmentGuru — It’s Friday — 0DTE day
Volatility tends to pick up into the close, so risk management is key. Here’s what’s on radar today:
$TSLA
$NVDA
$ASTS
$ONDS
$NVO
$AMD↗
Jan 16
The Future Investors — $NVO UK regulators approved a higher 7.2 mg weekly dose of Novo Nordisk’s Wegovy for obesity patients (BMI ≥30), expanding treatment options beyond the current 2.4 mg limit 💉🇬🇧…↗
Jan 16
KaizenInvestor — @TacticzH now it is up to the $NVO management to make the most of the GLP-1 pill timeline advantage↗
Jan 15
Lando — @Leo_Traydes Lmao I knew $hims was a ticking bomb. Healthcare is hard to break into and they don’t have the scale others have like $LLY or $NVO. Sure it’s good but I don’t typicall…↗
Jan 15
KaizenInvestor — @WealthyReadings $LLY has taken a lot of market share away from $NVO. Novo can fight back as their pill is approved while the Lilly pill approval has postponed. Still there is enou…↗
Jan 15
Mike Investing — 2 weeks ago, I shared my top picks for 2026.
Since then…
$ONDS +40%
$ASTS +33%
$RKLB +26%
$NVO +15%
$NBIS +15%
$ZETA +10%
$BABA +10%
The main move for all these picks has yet t…↗
Jan 14
Adam Feuerstein ✡️ — $NVO CEO Mike Doustdar was our guest on this week's live taping of the Readout LOUD. And yes, he spoke fairly plainly about his ambition to acquire another developer of obesity dru…↗
Jan 13
Mike Investing — $NVO is the most undervalued healthcare stock, but it won’t stay this way for long …
There is a clear ongoing valuation gap between $LLY & $NVO despite them sharing the same GLP-1…↗
Jan 13
InvestmentGuru — HIGH-CONVICTION STOCKS THAT CAN TRANSFORM YOUR PORTFOLIO OVER THE NEXT FEW YEARS
AI & Software
$PLTR $IONQ $RBLX $PATH $ZETA
AI automation, data dominance, quantum computing, and…↗
Jan 13
Mike Investing — These 6 sectors will greatly dominate the markets in 2026…
Space ~ $ASTS, $RKLB, $PL, $RDW
AI ~ $IREN, $NBIS, $ZETA
Healthcare ~ $NVO, $UNH, $OSCR
Drones ~ $ONDS
Robotics ~ $T…↗
Jan 11
Mike Investing — A portfolio involving these 10 picks will dominate & outperform the markets by a far margin in 2026…
1. $ONDS ~ Provides the secure & jam-resistant communication for autonomous dr…↗
Jan 11
Black Panther Capital — 👀 37 STOCKS THAT WILL 6X YOUR PORTFOLIO WEALTH NEXT 5 YEARS:
AI and Software:
$PATH
$ZETA
$PLTR
$IONQ
$RBLX
Fintech:
$SOFI
$PYPL
$LMND
$OPEN
$HOOD
Semiconductors:
$MU
$TSM
$PO…↗
Jan 11
KaizenInvestor — @TacticzH If you look at the 5-year CAGR instead of the 10-year CAGR, he would have noticed that $LLY is growing at least double the amount of $NVO in revenue and EPS.
That said…↗
Jan 10
KaizenInvestor — @TacticzH $NVO my clear favourite from the list↗
Jan 10
InvestmentGuru — $NVO and $AMZN Weight‑Loss Distribution Deal — What It Means for $HIMS
Novo Nordisk ($NVO) is now expanding access to its popular Wegovy weight‑loss pill through Amazon Pharmacy,…↗
Jan 10
Mike Investing — The healthcare sector is going to make a major comeback in 2026…
Here are 3 healthcare picks that you need in your portfolio to capture the incoming squeeze:
1. $NVO ~ A clear le…↗
Jan 10
InvestmentGuru — 5 Core Sectors Your Portfolio Should Be Focused On for 2026.
The next market cycle will be driven by power, compute, connectivity, health, and automation. Positioning early acros…↗
Jan 10
KaizenInvestor — @TacticzH $NVO will do great for you in the next few months 👌🏼↗
Jan 10
KaizenInvestor — @meeijer Would buy $NVO, $HIMS atm. Would hold $NBIS, $GOOGL, and $ASML.↗
Jan 9
Mike Investing — I’ve made generational wealth in 2025 for many, and I’ll do it yet again in 2026.
These are the 10 picks you need in your portfolio to succeed this year:
1. $ONDS ~ Autonomous de…↗
Jan 9
Mike Investing — There are 5 main sectors that’ll dominate the markets in 2026…
Space ~ $RKLB, $ASTS, $PL, $RDW
Drones ~ $ONDS
AI ~ $IREN, $NBIS, $ZETA
Robotics ~ $TSLA, $PATH, $RR
Healthcare…↗
Jan 9
Mike Investing — The 2026 stock picks have been on a historic run…
$ONDS +46%
$ASTS +39%
$NVO +14%
$RKLB +22%
$ZETA +21%
$NBIS +14%
$PATH +3%
$IREN +23%
$UNH +5%
This year is going to be life ch…↗
Jan 9
KaizenInvestor — Highly anticipated news. $HIMS moved to other high groth verticals the moment the deal with $NVO collapsed.
Still I expect the $NVO pill to boom. It would have brought loads of c…↗
The Future Investors — $NVO $AMZN Amazon Pharmacy will sell Novo Nordisk’s FDA-approved Wegovy weight-loss pill, costing $25/month with insurance or starting at $149/month cash, with kiosk availability c…↗
Jan 9
Shay Boloor — $AMZN Pharmacy is now offering $NVO Wegovy with home delivery across all 50 states.
The move expands nationwide access to GLP-1 obesity treatment through Amazon’s pharmacy platfor…↗
Jan 9
Mike Investing — These 10 picks should all be in your portfolio for 2026…
1. $ONDS ~ building the next generation of autonomous, defense, security & drone systems.
2. $ZETA ~ enables AI powered cu…↗
Jan 9
Mike Investing — 2026 is going to be a year full of generational opportunities for growth stocks…
$ONDS will be $40+
$OSCR will be $32+
$NVO will be $85+
$ZETA will be $50+
$ASTS will be $220+…↗
KaizenInvestor — $NVO is by far the cheapest pharma stock at the moment. It has a current P/E of 15.7 and a 5-year (CAGR) EPS growth of 22.19%. If they continue this EPS growth, the P/E will be onl…↗
Jan 8
InvestmentGuru — Healthcare stocks could attract buying interest, presenting potential opportunities for both growth and defensive plays.
$NVO
$HIMS
$ABCL
$RXRX
$PRME
$UNH
$OSCR↗
Jan 7
Mike Investing — These sectors are going to dominate the markets in 2026, and should be your portfolio’s primary focus…
1. AI ~ $NBIS, $IREN, $PATH, $ZETA, $CIFR
2. Space ~ $ASTS, $RKLB, $PL
3.…↗
Jan 7
KaizenInvestor — @Ron_Trades $NVO is less risk but also less rewarding imo↗
Jan 7
InvestmentGuru — $PATH and $NVO stand out as strong long-term buying opportunities at current levels.
$PATH offers leveraged exposure to automation and AI-driven efficiency as enterprises increasi…↗
Jan 7
Mike Investing — I’ve said it before, and I’ll say it again…
You do not own enough $NVO.
$NVO is going to be the next healthcare stock to see an aggressive V shape rebound.
With a 25% YoY EPS, 2…↗
Jan 7
Mike Investing — There are 5 core sectors your portfolio needs to be focused on for 2026:
1. Space ~ $ASTS, $RKLB, $PL
These companies are building the next generation of space infrastructure.
2.…↗
InvestmentGuru — $NVO interesting to watch today
Novo Nordisk Launches $149 Wegovy Pill, Expanding Access to GLP-1 Weight-Loss Drugs↗
Jan 6
Black Panther Capital — @meeijer It could very much have +30% if things continue well for $NVO. Whats your PT for 26?↗
Jan 6
Black Panther Capital — @TacticzH It’s going up up up up up. Honestly, on behalf of all $NVO that bought during the falling knife I’m happy. They deserve it after showing patience↗
Jan 5
The Future Investors — $NVO Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S. 💊🇺🇸
Available via major pharmacies & telehealth providers, starting at around $149/mont…↗
Jan 4
Mike Investing — These 5 sectors are going to lead the markets in 2026, and should be your primary focus…
1. Space ~ $ASTS, $RKLB, $PL
2. AI Infrastructure ~ $NBIS, $IREN, $CRWV
3. AI chips & Te…↗
Jan 3
Shay Boloor — 15 NAMES THAT COULD BOUNCE BACK IN 2026
1. $PYPL | PayPal (~81% drawdown)
2. $BMNR | Bitmine (~77% drawdown)
3. $FISV | Fiserv (~72% drawdown)
4. $VG | Venture Global (~71% drawdo…↗
Jan 3
Mike Investing — There are 4 main sectors your portfolio should be mainly focused upon for 2026…
1. AI & data centers ~ $NBIS, $IREN, $CIFR, $PATH, $ZETA
These picks power the AI boom through auto…↗
Jan 2
Mike Investing — There are 5 main sectors that will dominate the markets in 2026 that you need to be invested in…
Space ~ $ASTS, $RKLB
Drones ~ $ONDS
AI ~ $IREN, $NBIS, $ZETA
Robotics ~ $TSLA,…↗
Jan 2
Tradable Astronaut — @TLAMB91 Common theme is bounce at 9 MA on yearly charts it seems.
Speaking of which $NVO is there rn↗
Jan 1
Mike Investing — 6: Novo Nordisk ~ $NVO
Dominating the GLP-1 market, and with obesity and diabetes drugs driving demand; growth is visibly guaranteed this year.
With a 20%+ YoY revenue growth, 4…↗
Jan 1
KaizenInvestor — @meeijer Yes, I think so as well. $NVO is a very strong pick as well atm, undervalued imo.↗
Jan 1
Mike Investing — Below are the top 10 picks for 2026 that will most likely outperform the markets…
1. $ONDS
2. $ZETA
3. $NBIS
4. $IREN
5. $ASTS
6. $RKLB
7. $NVO
8. $TSLA
9. $AMZN
10. $PATH
Do not…↗
Black Panther Capital — ONE stock to hold the rest of your life, which stock would you pick?
$IREN
$NBIS
$CIFR
$META
$GOOG
$AMZN
$AMD
$MSFT
$NVDA
$PLTR
$HIMS
$NVO
You name it. What’s your life-long pick…↗
Dec 28
Leandro — I don’t have a very strong view on Novo $NVO but pretty sure that the launch of Oral Wegovy in and of itself is not the reason why it’s a long
Supply of oral/injectables GLP-1s is…↗
Dec 28
InvestmentGuru — 10 stocks that is buying opportunity in this market, for long term.
$NFLX — Streaming Giant Still Printing Cash. Netflix continues to dominate global streaming with expanding mar…↗
The Future Investors — 4 quality stocks having a tough year 🌠
Who’s your favourite rebound stock for 2026? ✨
Choose your fighter!🥊🚀
$ADBE $NVO $CRM $DUOL https://t.co/Y8MkvqCItn↗
Dec 26
Mike Investing — This year generational wealth was made via a wide variety of stock picks…
In 2025 I called out:
1. $ASTS at $36
2. $HOOD at $21
3. $PLTR at $62
4. $RKLB at $37
5. $TSLA at $210…↗
Dec 25
Mike Investing — I’m officially calling it…
$NVO is going to be the next healthcare stock to see a major V shape rally back into ATH’s territory in 2026.
Sitting at a 5 year low, and only at a 12…↗
Dec 24
Mike Investing — This year I bottom called and caught…
$TSLA at $210 and ran to $498+
$ASTS at $36 and ran to $102+
$RKLB at $37 and ran to $79+
$HOOD at $21 and ran to $153+
$PLTR at $62 and…↗
Dec 23
Black Panther Capital — 🤯 MARKET IS CHANGING FOREVER!
Today my dad arrived for Christmas.
On his 3 hours drive over here, he listened to podcast about stocks.
He has been trading for 30 years.
Legi…↗
Dec 23
Leandro — Didn't expect to be publishing this the day Oral Wegovy got approved in the US, but here we are.
'The Great (Oral) GLP-1 Scare: Why The Stevanato Narrative is Flawed.'
With the (…↗
Dec 23
InvestmentGuru — Morning news :
• FDA Approves Novo Nordisk's Wegovy Pill for Weight Loss Management $NVO
• Tesla Highlights FSD Reliability During Waymo Outage $TSLA
• Alibaba Considers Major A…↗
Dec 23
Leandro — Funny that Novo’s Oral Wegovy got approved just last night…because an article on GLP1s (oral vs injectable) is coming out today at Best Anchor Stocks…
$NVO $STVN $LLY↗
Dec 23
KaizenInvestor — @meeijer Lots of good news for $NVO in short-term. Might be time to step in.↗
Dec 23
The Future Investors — $NVO The FDA approved the first GLP-1 weight-loss pill from Novo Nordisk, offering an oral alternative to Wegovy injections 💊💉
The pill launches in early 2026, priced from $149/…↗
Mike Investing — It’s obvious that $NVO is going to be the next healthcare stock to see an aggressive V shape recovery…
With a 25% YoY EPS, 24% Revenue growth YoY, and at just a 12x P/E shows how…↗
InvestmentGuru — First GLP-1 Weight-Loss Pill Approved in the U.S.
U.S. regulators have approved the first oral GLP-1 weight-loss drug—a tablet formulation from $NVO (Novo Nordisk), based on the s…↗
Dec 22
mon — $NVO First GLP-1 pill to gain approval in the US.
This is a big deal. 🧐
It is expected to launch in early 2026, which is perfect timing, as people will be looking to lose weight…↗
Dec 22
Shay Boloor — $NVO said the FDA approved the first oral GLP-1 pill for weight management in the U.S. with trial data showing ~16.6% mean weight loss with adherence.
The company expects a U.S. l…↗
Dec 22
KaizenInvestor — Biotech & Genomics is the 2nd largest growing TAM globally. Despite this potential, the sector remained stagnant in 2025. While capital flooded into AI, pharma was ignored. I expec…↗
Dec 22
KaizenInvestor — @TacticzH Made a post about it last night if you want the full story. Also commented on your $NVO post why I’m bullish in the whole pharma/GLP-1 sector.
In short GLP-1 is not onl…↗
Dec 21
KaizenInvestor — @TacticzH The pharmaceutical sector appears fundamentally undervalued at current levels. This dislocation is largely driven by the massive institutional capital rotation into the A…↗
Dec 21
KaizenInvestor — $HIMS stands out as one of my highest-conviction picks for 2026. However, the stock is currently facing three distinct headwinds. Below, I outline these challenges and explain why…↗
Dec 20
Mike Investing — These sectors are going to dominate 2026 and should be your top portfolio priorities…
Space: $ASTS, $RKLB
AI: $ZETA, $ORCL, $IREN, $NBIS, $PLTR, $AMD
Robotics: $TSLA, $RR, $ONDS…↗
Dec 15
KaizenInvestor — @meeijer Very bullish news for $NVO, I see them doing really well into 2026.↗
Dec 12
Mike Investing — $NVO is clearly a no brainer to purchase at the current valuation it’s positioned at…
Sitting at a 5 year low & trading at just a 12x P/E shows just how undervalued $NVO reall…↗
Dec 4
Adam Feuerstein ✡️ — Last night at the CTAD meeting, $NVO presented the EVOKE studies of oral semaglutide in Alzheimer's disease.
It's hard to tell, but yes, there are two lines on each of those grap…↗
— $NVO is sitting at a 5 year low trading at just a 12x P/E…
It’s clear that $NVO will be the next healthcare stock to see a euphoric squeeze.
With 24% YoY revenue growth, 25% YoY…
Adam Feuerstein ✡️ — @A_May_MD Hasn't $NVO already reported amycretin ph2 results in obesity? In January?↗
Nov 25
The Future Investors — You have $100,000 to invest 💰
Two weight-loss titans are on the table — but you can only choose one for the next 5 years $LLY $NVO
Which do you pick, and why? 🤔 https://t.co/bf…↗
Nov 24
Adam Feuerstein ✡️ — Novo Nordisk’s $NVO semaglutide fails to slow Alzheimer’s progression https://t.co/UXa3LE12vW via @DrewQJoseph↗
Nov 24
The Future Investors — $NVO Novo Nordisk is down 12% after the Evoke trials showed semaglutide failed to slow Alzheimer’s progression, forcing the company to end the extension phase 📉 💉
Does this chan…↗
Nov 24
Adam Feuerstein ✡️ — $NVO oral semaglutide EVOKE studies in Alzheimer's fail.
https://t.co/RLpLhvJXTF↗
Nov 23
Mike Investing — I’m officially calling it…
$NVO is the next healthcare stock to see an aggressive rebound rally towards ATH’s.
With a 25% YoY EPS, 24% Revenue growth YoY, and meanwhile insiders…↗
Nov 21
Adam Feuerstein ✡️ — Next week: We will certainly see $CAPR and $NVO study readouts, right?↗
Nov 19
Adam Feuerstein ✡️ — $NVO Very few people believe oral sema studies in Alzheimer's will succeed. Yet, Novo posted job openings for Alzheimer's positions just days ago...
@elaineywchen previews the lo…↗
Nov 11
Adam Feuerstein ✡️ — @avidresearch We’ve asked $NVO. They’re not saying. Here’s the CTAD agenda. EVOKE trials presentation Weds Dec. 3 at 5:10 pm PT
https://t.co/Oi8yErnIE8↗
Nov 11
Adam Feuerstein ✡️ — @avidresearch Evoke trials are being presented at CTAD but unclear if $NVO is going to top-line results prior. They’re not saying.↗
Nov 6
Adam Feuerstein ✡️ — Also, both $LLY and $NVO are receiving FDA priority review vouchers as part of this government deal.↗
Nov 6
Adam Feuerstein ✡️ — Trump announces deal with Lilly, Novo to expand access to weight loss drugs, cut prices https://t.co/CVaCTfcAZI via @_daniel_payne @elaineywchen $LLY $NVO↗
Nov 6
Mike Investing — @mikealfred @ericjackson $NVO most definitely!!↗
Nov 5
Adam Feuerstein ✡️ — $NVO Novo CEO, in bidding war with Pfizer $PFE, says Metsera’s $MTSR drugs would complement pipeline https://t.co/d5PARiot1Z via @DrewQJoseph↗
Nov 5
The Future Investors — 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸 𝗤𝟯 𝟮𝟬𝟮𝟱 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀 $NVO
EPS: $0.69 vs $0.66 est. ✅
Revenue: $11.52B vs $11.84B est. ❌
𝗢𝘂𝘁𝗹𝗼𝗼𝗸 𝟮𝟬𝟮𝟱
Revenue: 8.0%-11.0% vs 8.0% est.…↗
Nov 4
The Future Investors — $NVO $LLY Eli Lilly and Novo Nordisk are nearing a deal with the White House to price their obesity drugs at $149/month in exchange for Medicare coverage, potentially announced thi…↗
Nov 4
Adam Feuerstein ✡️ — Bidding war between Pfizer, Novo Nordisk $NVO for obesity startup Metsera $MTSR escalates
Next up: $PFE earnings call this morning
https://t.co/EViuZSlDhm via @elaineywchen↗
Nov 2
Mike Investing — These 5 stocks are the most undervalued in the entire market as of right now…
1. $NVO
2. $JD
3. $UNH
4. $ADBE
5. $PYPL
Expect these setups to see euphoric upside moves over the n…↗
Nov 1
The Future Investors — Next week we’re picking up right where we left off — with another busy wave of earnings ahead 📊
Monday: $PLTR, $HIMS
Tuesday: $UBER, $SHOP, $ANET, $AXON, $AMD
Wednesday: $NVO, $H…↗
— $NVO official bid for $MTSR. What will $PFE do?
https://t.co/yb3nQjGKAB
Adam Feuerstein ✡️ — FDA declares Novo Nordisk $NVO (Catalent) plant, key to drug manufacturing for some biotechs, out of compliance. Impacting $SRRK and $REGN today.
https://t.co/LLlei1xM7X via @el…↗
Oct 9
Adam Feuerstein ✡️ — Novo Nordisk $NVO to buy Akero Therapeutics $AKRO, picking up promising MASH drug https://t.co/NJhLwz1wHL↗
— These 5 stocks are at extreme oversold levels right now and all will see massive returns over the next few weeks…
$OSCR
$ZETA
$LMND
$NVO
$UNH
Don’t miss out on these once in a li…
Adam Feuerstein ✡️ — $NVO discontinued development of FGF21-targeted MASH drug zalfermin. $AKRO $ETNB↗
Aug 1
Adam Feuerstein ✡️ — $REGN regulatory update:
Expects Eylea HD pre-filled syringe and RVO approval delays (August PDUFAs) due to FDA general site inspection issues at Catalent's Indiana manufacturing…↗
Aug 1
Puru Saxena — There are NO "safe" stocks.
ALL stocks go through stages:
Stage 1 - base
Stage 2 - uptrend
Stage 3 - top
Stage 4 - downtrend
Even well-established companies' stocks decline 50…↗
Aug 1
Puru Saxena — This is NovoNordisk - a "safe" investment.
$NVO down 67% in a year!
Stage analysis would've booked your gain before this horrendous "Stage 4" decline. This is why we use "stage…↗